ReviewClinical microbiology reviews2019
Phage Therapy in the Postantibiotic Era.
Review in Clinical microbiology reviews, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 565 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
565 citing papers in PubMed, 1 synthesis or guideline pooled it, 930 citations in OpenAlex.
- Precision phage therapy in the AI/ML era: a systematic review of discovery-to-clinical translation evidence.Frontiers in microbiology · 2026Pooled it
- Phenotypic heterogeneity and genetic mechanisms of phage resistance in hypervirulent carbapenem-resistantVirulence · 2026Article
- Potential Roles of Escherichia coli in IgA Nephropathy: Evidence, Mechanistic Hypotheses and Microbiota-Targeted Strategies.Microbial biotechnology · 2026Review
- Harnessing phage-ciprofloxacin synergy to overcome multidrug-resistant infections and biofilm persistence.Archives of microbiology · 2026Article
- Phage Genomics and Bioinformatics in Therapeutic Development: Evidence Limits, Validation Gates, and Translational Decision-Making.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Review
- Innovative Applications of Artificial Intelligence in Bacteriophage Research: A New Chapter in Future Medicine.Microorganisms · 2026Review
- Biofilm Dynamics and Antimicrobial Resistance in Rabbit Odontogenic Infections: A One Health Perspective.Pathogens (Basel, Switzerland) · 2026Review
- Eradication of catheter-associated MDR Acinetobacter baumannii biofilms mediated by novel phage encoded depolymerase activity.NPJ biofilms and microbiomes · 2026Article
- A Lytic Bacteriophage Cocktail Attenuates Carbapenem-Resistant Klebsiella pneumoniae-Acinetobacter baumannii Mixed-Species Biofilms and Reshapes Transcriptional Responses.Microbial biotechnology · 2026Article
- Bacteriophage therapy and antimicrobial resistance: a scoping review using the "One Health" framework.Infection · 2026Review
- Phage and CRISPR based precision antimicrobials: a dual strategy against multidrug-resistant bacteria.Molecular biology reports · 2026Review
- WaaL-WaaP receptor cross-talk drives phage-induced collateral sensitivity to colistin in Salmonella Pullorum.Veterinary research · 2026Article
- Development andMicrobiology spectrum · 2026Article
- Characterization ofMicrobiology spectrum · 2026Article
- Synergistic potential of probiotics and bacteriophages in combating multidrug-resistant microbial infections: A novel therapeutic strategy for the post-antibiotic era.New microbes and new infections · 2026Review
- Novel Therapeutic Approaches and Alternatives to Antibiotic Therapy for Drug-Resistant Intra-Abdominal Infections.Antibiotics (Basel, Switzerland) · 2026Review
- Short-Term Bacteriophage Exposure Is Associated with Shifts in Antibiotic Susceptibility Profiles of ClinicalMicroorganisms · 2026Article
- Ec_Ou_ZC1, a new Tunavirus, reveals Cor superinfection exclusion and differential Avs susceptibility across Drexlerviridae subfamilies.BMC microbiology · 2026Article
- Mechanism ofMicroorganisms · 2026Article
505 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotic resistance is arguably the biggest current threat to global health. An increasing number of infections are becoming harder or almost impossible to treat, carrying high morbidity, mortality, and financial cost. The therapeutic use of bacteriophages, viruses that infect and kill bacteria, is well suited to be part of the multidimensional strategies to combat antibiotic resistance. Although phage therapy was first implemented almost a century ago, it was brought to a standstill after the successful introduction of antibiotics. Now, with the rise of antibiotic resistance, phage therapy is experiencing a well-deserved rebirth. Among the admittedly vast literature recently published on this topic, this review aims to provide a forward-looking perspective on phage therapy and its role in modern society. We cover the key points of the antibiotic resistance crisis and then explain the biological and evolutionary principles that support the use of phages, their interaction with the immune system, and a comparison with antibiotic therapy. By going through up-to-date reports and, whenever possible, human clinical trials, we examine the versatility of phage therapy. We discuss conventional approaches as well as novel strategies, including the use of phage-antibiotic combinations, phage-derived enzymes, exploitation of phage resistance mechanisms, and phage bioengineering. Finally, we discuss the benefits of phage therapy beyond the clinical perspective, including opportunities for scientific outreach and effective education, interdisciplinary collaboration, cultural and economic growth, and even innovative use of social media, making the case that phage therapy is more than just an alternative to antibiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.